Afshar, M., Knapp, C. M., Sarid-Segal, O., Devine, E., Colaneri, L. S., Tozier, L., Waters, M. E., Putnam, M. A., & Ciraulo, D. A. (2012). The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. American Journal of Drug and Alcohol Abuse, 38, 181–186.

Article  PubMed  Google Scholar 

Anttila, S. A., & Leinonen, E. V. (2001). A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Reviews, 7, 249–264.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Araos, P., Vergara-Moragues, E., Pedraz, M., Pavón, F. J., Campos, C. R., Calado, M., Ruiz, J. J., García-Marchena, N., Gornemann, I., Torrens, M., & Rodríguez de Fonseca, F. (2014). Psychopathological comorbidity in cocaine users in outpatient treatment. Adicciones, 26, 15–26.

Article  PubMed  Google Scholar 

Bahi, A. (2016). Sustained lentiviral-mediated overexpression of microRNA124a in the dentate gyrus exacerbates anxiety- and autism-like behaviors associated with neonatal isolation in rats. Behavioural Brain Research, 311, 298–308.

Article  CAS  PubMed  Google Scholar 

Bahi, A., Al Mansouri, S., Al Memari, E., Al Ameri, M., Nurulain, S. M., & Ojha, S. (2014a). β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiology & Behavior, 135, 119–124.

Article  CAS  Google Scholar 

Bahi, A., Schwed, J. S., Walter, M., Stark, H., & Sadek, B. (2014b). Anxiolytic and antidepressant-like activities of the novel and potent non-imidazole histamine H3 receptor antagonist ST-1283. Drug. Des. Devel. Ther., 8, 627–637.

PubMed  PubMed Central  Google Scholar 

Barbosa-Méndez, S., & Salazar-Juárez, A. (2019). Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal. Journal of Psychopharmacology, 33, 589–605.

Article  PubMed  Google Scholar 

Barbosa-Méndez, S., Leff, P., Arías-Caballero, A., Hernández-Miramontes, R., Heinze, G., & Salazar-Juárez, A. (2017a). Mirtazapine attenuates cocaine seeking in rats. Journal of Psychiatric Research, 92, 38–46.

Article  PubMed  Google Scholar 

Barbosa-Méndez, S., Matus-Ortega, M., & Salazar-Juárez, A. (2017b). Synergistic interactions between mirtazapine and prazosin prevent the induction and expression of behavioral sensitization to cocaine in rats. Physiology & Behavior, 180, 137–145.

Article  Google Scholar 

Barbosa-Méndez, S., Matus-Ortega, M., Jacinto-Gutiérrez, S., & Salazar-Juárez, A. (2018). Mirtazapine impairs acquisition and reinstatement of cocaine-induced place preference in rats. European Journal of Pharmacology, 820, 183–190.

Article  PubMed  Google Scholar 

Bentley, G. A., Newton, S. H., & Starr, J. (1983). Studies on the antinociceptive action of alpha agonist drugs and their interactions with opioid mechanisms. British Journal of Pharmacology, 79, 125–134.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009). Pharmacologic alternatives to antidepressants in posttraumatic stress disorder, a systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 169–180.

Article  CAS  PubMed  Google Scholar 

Bijak, M. (1989). Antidepressant drugs potentiate the alpha 1-adrenoceptor effect in hippocampal slices. European Journal of Pharmacology, 166, 183–191.

Article  CAS  PubMed  Google Scholar 

Bittolo, T., Raminelli, C. A., Deiana, C., Baj, G., Vaghi, V., Ferrazzo, S., Bernareggi, A., & Tongiorgi, E. (2016). Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice. Science and Reports, 6, 19796.

Article  CAS  ADS  Google Scholar 

Byers, M. G., Allison, K. M., Wendel, C. S., & Lee, J. K. (2010). Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans, an assessment of long-term comparative effectiveness and safety. Journal of Clinical Psychopharmacology, 30, 225–229.

Article  PubMed  Google Scholar 

Chandrasekaran, P. K. (2008). Employing mirtazapine to aid benzodiazepine withdrawal. Singapore Medical Journal, 49, e166–e167.

CAS  PubMed  Google Scholar 

Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., Tansella, M., & Barbui, C. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants, a multiple-treatments meta-analysis. Lancet, 373, 746–758.

Article  CAS  PubMed  Google Scholar 

Conway, K. P., Compton, W., Stinson, F. S., & Grant, B. F. (2006). Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders, results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 67, 247–257.

Article  CAS  PubMed  Google Scholar 

Cornelius, J. R., Douaihy, A. B., Clark, D. B., Chung, T., Wood, D. S., & Daley, D. (2012). Mirtazapine in Comorbid Major Depression and Alcohol Dependence. An Open-Label Trial. J. Dual Diagn., 8, 200–204.

PubMed  Google Scholar 

Cornelius, J. R., Douaihy, A. B., Clark, D. B., Daley, D. C., Chung, T. A., Wesesky, M. A., Wood, D. S., & Salloum, I. (2013). Mirtazapine in Comorbid Major Depression and Alcohol Use Disorder, A Long-Term Follow-Up Study. Journal of Addictive Behaviors, Therapy & Rehabilitation, 3, 1560.

Google Scholar 

Cornelius, J. R., Chung, T., Douaihy, A. B., Kirisci, L., Glance, J., Kmiec, J., FitzGerald, D., Wesesky, M. A., & Salloum, I. (2016). Mirtazapine in comorbid major depression and an alcohol use disorder, A double-blind placebo-controlled pilot trial. Psychiatry Research, 242, 326–330.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crawley, J., & Goodwin, F. K. (1980). Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacology, Biochemistry and Behavior, 13, 167–170.

Article  CAS  PubMed  Google Scholar 

Croom, K. F., Perry, C. M., & Plosker, G. L. (2009). Mirtazapine, A review of its use in major depression and other psychiatric disorders. CNS Drugs, 23, 427–452.

Article  CAS  PubMed  Google Scholar 

Cryan, J. F., Page, M. E., & Lucki, I. (2005). Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology Berl., 182, 335–344.

Article  CAS  PubMed  Google Scholar 

de Oliveira, C., Mdo, C., da Silva, F. C., Silva, M. I., Moura, B. A., Macêdo, D. S., Woods, D. J., Fonteles, M. M., de Vasconcelos, S. M., & de Sousa, F. C. (2012). Reversal of cocaine withdrawal-induced anxiety by ondansetron, buspirone, and propranolol. Behavioural Brain Research, 231, 116–123.

Article  Google Scholar 

Doze, V. A., Handel, E. M., Jensen, K. A., Darsie, B., Luger, E. J., Haselton, J. R., Talbot, J. N., & Rorabaugh, B. R. (2009). alpha (1A.- and alpha (1B.-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Research, 1285, 148–157.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drapier, D., Bentué-Ferrer, D., Laviolle, B., Millet, B., Allain, H., Bourin, M., & Reymann, J. M. (2007). Effects of acute fluoxetine, paroxetine, and desipramine on rats tested on the elevated plus-maze. Behavioural Brain Research, 176, 202–209.

Article  CAS  PubMed  Google Scholar 

D’Souza, M. S., & Markou, A. (2010). Neural substrates of psychostimulant withdrawal-induced anhedonia. Current Topics in Behavioral Neurosciences, 3, 119–178.

Article  PubMed  Google Scholar 

El Hage, C., Rappeneau, V., Etievant, A., Morel, A. L., Scarna, H., Zimmer, L., & Bérod, A. (2012). Enhanced anxiety observed in cocaine withdrawn rats is associated with altered reactivity of the dorsomedial prefrontal cortex. PLoS ONE, 7, e43535.

Article  PubMed  PubMed Central  ADS  Google Scholar 

Erb, S., Kayyali, H., & Romero, K. (2006). A study of the lasting effects of cocaine pre-exposure on anxiety-like behaviors under baseline conditions and in response to central injections of corticotropin-releasing factor. Pharmacology, Biochemistry and Behavior, 85, 206–213.

Article  CAS  PubMed  Google Scholar 

Fox, H. C., Anderson, G. M., Tuit, K., Hansen, J., Kimmerling, A., Siedlarz, K. M., Morgan, P. T., & Sinha, R. (2012). Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals, preliminary findings. Alcoholism, Clinical and Experimental Research, 36, 351–360.

Article  CAS  PubMed  Google Scholar 

Gambi, F., De Berardis, D., Campanella, D., Carano, A., Sepede, G., Salini, G., Mezzano, D., Cicconetti, A., Penna, L., Salerno, R. M., & Ferro, F. M. (2005). Mirtazapine treatment of generalized anxiety disorder, a fixed dose, open label study. Journal of Psychopharmacology, 19, 483–487.

Article  CAS  PubMed  Google Scholar 

Gawin, F. H., & Kleber, H. D. (1986). Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical Observations. Arch Gen Psychiatry, 43, 107–113.

Article  CAS  PubMed  Google Scholar 

Goodnick, P. J., Puig, A., DeVane, C. L., & Freund, B. V. (1999). Mirtazapine in major depression with comorbid generalized anxiety disorder. Journal of Clinical Psychiatry, 60, 446–448.

Article  CAS  PubMed  Google Scholar 

Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders, results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry, 61, 807–816.

Article  PubMed  Google Scholar 

Grasmäder, K., Verwohlt, P. L., Kühn, K. U., Frahnert, C., Hiemke, C., Dragicevic, A., von Widdern, O., Zobel, A., Maier, W., & Rao, M. L. (2005). Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry, 38, 113–117.

Article  PubMed